Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

NCT06824987 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

APOL1-Mediated Kidney Disease

Interventions

COMBINATION_PRODUCT: AZD2373-Arm 1
COMBINATION_PRODUCT: AZD2373-Arm 2
COMBINATION_PRODUCT: Placebo
DEVICE: APOL1 Genotyping Clinical Trial Assay

Sponsor

AstraZeneca